SM04554SM04554is a molecule that acts at the level of the skin androgen receptor, blocking dihydrotestosterone (DHT) from binding to the receptor in the cell. The molecule has a unique mechanism that acts at the skin surface, and is quickly metabolized to free inactive cortexolone, a sub

RU58841RU-58841, also known asPSK-3841orHMR-3841, is anonsteroidal antiandrogen(NSAA) which was initially developed in the 1980s byRoussel Uclaf, the French pharmaceutical company from which it received its name. It was formerly under investigation by ProStr

WAY 316606WAY 316606 is a selective small-molecule inhibitor of secreted frizzled-related protein-1 (sFRP-1) with EC50 value of 0.65 μM .The Wnt signaling has been proved to be a drug target of treatment for metabolic bone diseases such as osteoporosis. The studies found that loss-of-function mutat

CB-03-01CB-03-01 is a topical anti androgen, like RU58841, which has local anti androgenic effects when applied to the skin. RU58841 is a very effective topical treatment for hair loss (male pattern baldness), how ever some users might experience side effects like fatigue and a decreased libid

FevipiprantFevipiprant(INN; code nameQAW039) is adrugbeing developed byNovartiswhich acts as a selective, orally availableantagonistof theprostaglandin D2 receptor 2(DP2or CRTh2).As of 2016, it is inphase IIIclinica

SetipiprantSetipiprant is an orally available, selective CRTH2 antagonist. CRTH2 is a G protein-coupled receptor for PGD2.IC50 value: 6.0 nMTarget: PGD2in vitro: Setipiprant is an orally available, selective CRTH2 (chemoattractant receptor-homologous molecule expressed on T helper [Th]-2 cells